OTC Markets OTCPK - Delayed Quote USD

Eisai Co., Ltd. (ESAIY)

Compare
7.27
+0.03
+(0.41%)
At close: January 24 at 3:00:00 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
741,751,000.00
741,751,000.00
744,402,000.00
756,226,000.00
645,942,000.00
Cost of Revenue
155,333,000.00
155,333,000.00
177,837,000.00
174,831,000.00
161,310,000.00
Gross Profit
586,417,000.00
586,417,000.00
566,566,000.00
581,395,000.00
484,632,000.00
Operating Expense
533,010,000.00
533,010,000.00
526,526,000.00
527,645,000.00
433,120,000.00
Operating Income
53,407,000.00
53,407,000.00
40,040,000.00
53,750,000.00
51,512,000.00
Net Non Operating Interest Income Expense
8,416,000.00
8,416,000.00
4,973,000.00
709,000.00
785,000.00
Pretax Income
61,823,000.00
61,823,000.00
45,012,000.00
54,458,000.00
52,296,000.00
Tax Provision
18,040,000.00
18,040,000.00
-11,824,000.00
8,741,000.00
9,990,000.00
Net Income Common Stockholders
42,406,000.00
42,406,000.00
55,432,000.00
47,954,000.00
41,942,000.00
Diluted NI Available to Com Stockholders
42,406,000.00
42,406,000.00
55,432,000.00
47,954,000.00
41,942,000.00
Basic EPS
39.59
36.97
48.33
41.82
146.34
Diluted EPS
39.59
36.97
48.33
41.81
146.29
Basic Average Shares
1,147,195.89
1,147,193.29
1,147,028.00
1,146,740.00
286,616.00
Diluted Average Shares
1,147,211.89
1,147,193.29
1,147,044.00
1,146,916.00
286,713.00
Total Operating Income as Reported
53,408,000.00
53,408,000.00
40,040,000.00
53,750,000.00
51,511,000.00
Total Expenses
688,343,000.00
688,343,000.00
704,363,000.00
702,476,000.00
594,430,000.00
Net Income from Continuing & Discontinued Operation
42,407,000.00
42,407,000.00
55,432,000.00
47,954,000.00
41,942,000.00
Normalized Income
42,407,000.00
42,407,000.00
55,432,000.00
47,954,000.00
41,942,000.00
Interest Income
10,804,000.00
10,804,000.00
7,239,000.00
2,401,000.00
2,145,000.00
Interest Expense
2,388,000.00
2,388,000.00
2,266,000.00
1,692,000.00
1,360,000.00
Net Interest Income
8,416,000.00
8,416,000.00
4,973,000.00
709,000.00
785,000.00
EBIT
64,211,000.00
64,211,000.00
47,278,000.00
56,150,000.00
53,656,000.00
EBITDA
103,609,000.00
103,609,000.00
87,259,000.00
94,548,000.00
89,423,000.00
Reconciled Cost of Revenue
155,333,000.00
155,333,000.00
177,837,000.00
174,831,000.00
161,310,000.00
Reconciled Depreciation
39,398,000.00
39,398,000.00
39,981,000.00
38,398,000.00
35,767,000.00
Net Income from Continuing Operation Net Minority Interest
42,407,000.00
42,407,000.00
55,432,000.00
47,954,000.00
41,942,000.00
Normalized EBITDA
103,609,000.00
103,609,000.00
87,259,000.00
94,548,000.00
89,423,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
3/31/2021 - 2/2/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

0ND5.IL H. Lundbeck A/S
41.38
+1.79%
 
6FN.F Klaria Pharma Holding AB (publ.)
0.0736
-13.41%
 
SGIOY Shionogi & Co., Ltd.
7.29
-0.14%
 
CYTH Cyclo Therapeutics, Inc.
0.8210
-1.91%
 
2196.HK Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13.520
+1.50%
 
HLS.TO HLS Therapeutics Inc.
4.0200
-1.47%
 
ETON Eton Pharmaceuticals, Inc.
16.67
+2.65%
 
AMRX Amneal Pharmaceuticals, Inc.
8.68
-1.48%
 
TAK Takeda Pharmaceutical Company Limited
12.99
+0.54%
 
BGM BGM Group Ltd.
10.65
-0.28%